Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLFS NASDAQ:MDXG NASDAQ:STIM NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$20.64-2.1%$21.89$19.10▼$29.55$1.01B1.76409,147 shs458,242 shsMDXGMiMedx Group$7.11-1.8%$6.48$5.47▼$10.14$1.07B1.791.03 million shs651,301 shsSTIMNeuronetics$4.01-5.4%$3.82$0.52▼$5.92$280.70M1.781.11 million shs3.23 million shsTNDMTandem Diabetes Care$11.52-19.9%$17.73$9.98▼$47.60$958.48M1.461.76 million shs11.84 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions-2.13%-2.92%-8.47%-11.19%-6.39%MDXGMiMedx Group-1.80%-1.11%+1.57%-0.14%+13.40%STIMNeuronetics-5.42%-8.66%+17.25%-9.48%+114.44%TNDMTandem Diabetes Care-19.94%-26.06%-30.69%-49.87%-68.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLFSBioLife Solutions2.9504 of 5 stars3.53.00.00.02.42.50.6MDXGMiMedx Group2.6474 of 5 stars3.52.00.00.03.21.70.6STIMNeuronetics1.1792 of 5 stars2.31.00.00.02.01.70.6TNDMTandem Diabetes Care3.6362 of 5 stars3.11.00.04.93.40.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLFSBioLife Solutions 3.00Buy$31.0050.19% UpsideMDXGMiMedx Group 3.00Buy$12.0068.78% UpsideSTIMNeuronetics 2.67Moderate Buy$5.0024.69% UpsideTNDMTandem Diabetes Care 2.27Hold$25.80123.96% UpsideCurrent Analyst Ratings BreakdownLatest STIM, MDXG, TNDM, and BLFS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/7/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$59.00 ➝ $24.008/7/2025TNDMTandem Diabetes CarePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$30.00 ➝ $14.008/7/2025TNDMTandem Diabetes CareUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$20.00 ➝ $17.008/7/2025TNDMTandem Diabetes CareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $13.008/7/2025TNDMTandem Diabetes CareRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$45.00 ➝ $25.008/6/2025STIMNeuroneticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.007/31/2025MDXGMiMedx GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$11.00 ➝ $12.007/22/2025BLFSBioLife SolutionsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$30.007/15/2025MDXGMiMedx GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$11.007/9/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Sell$24.00 ➝ $14.006/16/2025TNDMTandem Diabetes CareTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$24.00(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLFSBioLife Solutions$82.25M12.00$0.12 per share172.15$7.52 per share2.74MDXGMiMedx Group$348.88M3.02$0.33 per share21.85$1.46 per share4.87STIMNeuronetics$74.89M3.54N/AN/A$0.48 per share8.35TNDMTandem Diabetes Care$940.20M0.82N/AN/A$4.01 per share2.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLFSBioLife Solutions-$20.18M-$0.29N/AN/AN/A-11.81%-0.66%-0.58%N/AMDXGMiMedx Group$42.42M$0.2133.8622.22N/A8.84%23.03%17.09%N/ASTIMNeuronetics-$43.71M-$1.13N/AN/AN/A-43.47%-156.36%-35.69%N/ATNDMTandem Diabetes Care-$96.03M-$2.78N/AN/AN/A-20.51%-59.02%-13.60%N/ALatest STIM, MDXG, TNDM, and BLFS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025BLFSBioLife Solutions-$0.02-$0.33-$0.31-$0.33$23.71 million$25.42 million8/6/2025Q2 2025TNDMTandem Diabetes Care-$0.40-$0.48-$0.08-$0.78$238.39 million$240.68 million8/5/2025Q2 2025STIMNeuronetics-$0.08-$0.15-$0.07-$0.15$36.80 million$38.11 million7/30/2025Q2 2025MDXGMiMedx Group$0.06$0.10+$0.04$0.06$90.79 million$98.61 million5/8/2025Q1 2025BLFSBioLife Solutions-$0.03$0.04+$0.07-$0.01$22.22 million$23.94 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLFSBioLife SolutionsN/AN/AN/AN/AN/AMDXGMiMedx GroupN/AN/AN/AN/AN/ASTIMNeuroneticsN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLFSBioLife Solutions0.014.733.74MDXGMiMedx Group0.084.393.90STIMNeuronetics1.402.442.28TNDMTandem Diabetes Care1.992.301.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLFSBioLife Solutions93.24%MDXGMiMedx Group79.15%STIMNeuronetics53.59%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipBLFSBioLife Solutions2.20%MDXGMiMedx Group1.70%STIMNeuronetics8.70%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLFSBioLife Solutions44047.83 million46.78 millionOptionableMDXGMiMedx Group870147.96 million145.44 millionOptionableSTIMNeuronetics18066.12 million60.36 millionOptionableTNDMTandem Diabetes Care2,65066.61 million65.34 millionOptionableSTIM, MDXG, TNDM, and BLFS HeadlinesRecent News About These CompaniesToday's Analyst Rating Update for Tandem Diabetes Care (TNDM) | TNDM Stock NewsAugust 7 at 7:49 PM | gurufocus.comTandem Diabetes Care (NASDAQ:TNDM) Sets New 52-Week Low - Should You Sell?August 7 at 3:48 PM | marketbeat.comInsulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags StockAugust 7 at 2:12 PM | benzinga.comTandem Diabetes Care, Inc. (TNDM) Stock forecastsAugust 7 at 1:36 PM | uk.finance.yahoo.comForecasting The Future: 4 Analyst Projections For Tandem Diabetes CareAugust 7 at 1:36 PM | benzinga.comTandem Diabetes Care issues voluntary device correction for certain insulin pumpsAugust 7 at 9:32 AM | reuters.comTandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin ...August 7 at 9:23 AM | gurufocus.comTandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin PumpsAugust 7 at 9:22 AM | gurufocus.comTandem Diabetes (NASDAQ:TNDM) Exceeds Q2 Expectations But Stock Drops 17%August 7 at 8:35 AM | finance.yahoo.comTandem Diabetes projects $1B sales for 2025 as international growth, pharmacy channel, and product innovation drive outlookAugust 7 at 8:35 AM | msn.comRedwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionAugust 7 at 8:34 AM | benzinga.comiA Global Asset Management Inc. Takes $3.17 Million Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)August 7 at 6:36 AM | marketbeat.comTandem Diabetes Care, Inc. (TNDM) Q2 2025 Earnings Call TranscriptAugust 7 at 3:01 AM | seekingalpha.comTandem Diabetes Care: Strong Revenue Performance and Promising Portfolio Justify Buy Rating Despite ChallengesAugust 6 at 11:53 PM | tipranks.comTandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to SayAugust 6 at 8:01 PM | zacks.comTandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Beats Revenue EstimatesAugust 6 at 6:51 PM | zacks.comTandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual ...August 6 at 5:13 PM | gurufocus.comTandem Diabetes Care Inc (TNDM) Q2 2025 Earnings: Revenue Surpasses Estimates at $240. ...August 6 at 5:13 PM | gurufocus.comTandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual ...August 6 at 5:12 PM | gurufocus.comTandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual GuidanceAugust 6 at 4:05 PM | businesswire.comTandem Diabetes Care Q2 2025 Earnings PreviewAugust 5 at 10:42 PM | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTIM, MDXG, TNDM, and BLFS Company DescriptionsBioLife Solutions NASDAQ:BLFS$20.64 -0.45 (-2.13%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$21.26 +0.63 (+3.03%) As of 08/7/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.MiMedx Group NASDAQ:MDXG$7.11 -0.13 (-1.80%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$6.97 -0.14 (-1.97%) As of 08/7/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.Neuronetics NASDAQ:STIM$4.01 -0.23 (-5.42%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$4.24 +0.23 (+5.64%) As of 08/7/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.Tandem Diabetes Care NASDAQ:TNDM$11.52 -2.87 (-19.94%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$11.61 +0.09 (+0.78%) As of 08/7/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Don't Mix the Signal for Noise in Super Micro Computer's Earnings Microsoft Stock Gains as Analysts Boost Price Targets Joby Deal Gives Blade New Direction, But Stock Lacks Lift Uber Technologies Is Driving Cash Flow: Ride It Higher for Life How DigitalOcean's Focus Is Fueling Explosive Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
